argenex (ARGX) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for argenex (NASDAQ: ARGX):

• 7/7/2026 – argenex had its price target raised by Royal Bank Of Canada from $890.00 to $945.00. They now have an “outperform” rating on the stock.
• 7/6/2026 – argenex was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 7/2/2026 – argenex had its price target raised by Bank of America Corporation from $1,016.00 to $1,088.00. They now have a “buy” rating on the stock.
• 6/25/2026 – argenex had its “buy” rating reaffirmed by HC Wainwright. They now have a $940.00 price target on the stock.
• 6/24/2026 – argenex had its price target raised by Morgan Stanley from $1,170.00 to $1,180.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – argenex had its “outperform” rating reaffirmed by Wedbush. They now have a $1,000.00 price target on the stock.
• 6/4/2026 – argenex had its “outperform” rating reaffirmed by Wedbush. They now have a $1,000.00 price target on the stock.
• 6/1/2026 – argenex had its price target raised by Wells Fargo & Company from $1,260.00 to $1,291.00. They now have an “overweight” rating on the stock.

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.